CBP-201-209

Purpose of this Study

Participants will receive the study drug rademikibart through a brief IV infusion along with standard treatment for an asthma or COPD flare-up. Researchers will collect information about medications, smoking history, hospital stays, breathing tests, blood and urine samples, and overall health. Participants will be followed for 42 days after receiving the study drug.

Who Can Participate?

Eligibility

Participants may be able to join if they are experiencing an acute flare-up of asthma or COPD that their doctor plans to treat with steroid medication. They must also have blood test results showing inflammation. This study is not for people whose breathing problems are caused by other medical conditions.

Age Range

18-85

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

This study is testing a new medicine called rademikibart for people with asthma or COPD. Rademikibart is designed to reduce inflammation that can make breathing problems worse. Researchers want to learn how well a single dose of the drug works, how quickly it may improve breathing, and how safe it is when given during an asthma or COPD flare-up.

Locations

Duke University Hospital
Duke Regional Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

Yes

Study Details

Full Title

A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-On Treatment for an Acute Exacerbation in Participants With Asthma or COPD With Type 2 Inflammation

Principal Investigator

Alexander
Limkakeng

Protocol Number

PRO00121353

Phase

II

Enrollment Status

Pending Open to Enrollment